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Drug abuse (DA) and addiction is a complex illness, broadly viewed as a neurobiological
impairment with genetic and environmental factors that influence its development and
manifestation. Abused substances can disrupt the activity of neurons by interacting with
many proteins, particularly G-protein coupled receptors (GPCRs). A few medicines that
target the central nervous system (CNS) can also modulate DA related proteins, such as
GPCRs, which can act in conjunction with the controlled psychoactive substance(s) and
increase side effects. To fully explore the molecular interaction networks that underlie
DA and to effectively modulate the GPCRs in these networks with small molecules for
DA treatment, we built a drug-abuse domain specific chemogenomics knowledgebase
(DA-KB) to centralize the reported chemogenomics research information related to DA
and CNS disorders in an effort to benefit researchers across a broad range of disciplines.
We then focus on the analysis of GPCRs as many of them are closely related with DA.
Their distribution in human tissues was also analyzed for the study of side effects caused
by abused drugs. We further implement our computational algorithms/tools to explore
DA targets, DA mechanisms and pathways involved in polydrug addiction and to explore
polypharmacological effects of the GPCR ligands. Finally, the polypharmacology effects
of GPCRs-targeted medicines for DA treatment were investigated and such effects can
be exploited for the development of drugs with polypharmacophore for DA intervention.
The chemogenomics database and the analysis tools will help us better understand
the mechanism of drugs abuse and facilitate to design new medications for system
pharmacotherapy of DA.
Keywords: drug abuse, GPCRs, polypharmacology, polydrug addiction, chemogenomics, cloud computation,
target prediction, systems pharmacology
INTRODUCTION
Drug abuse (DA) and addiction is a complex brain disease charac-
terized by compulsive drug craving, seeking, and use that persist
in spite of severe adverse consequences. The basic mechanisms of
DA have been explored for decades. It is well accepted that abused
substances can disrupt activity of normal nerve cells by interact-
ing with receptors in the brain, like G-protein coupled receptors
(GPCRs), and then activating the downstream signaling path-
ways, which comprise a host of kinases and transcription factors.
Specifically, there is a broad range of GPCRs related to the DA
and central nervous system (CNS) side effects, including recep-
tors of opioid, cannabinoid, and Serotonin. Further, it is esti-
mated that genetic factors play a significant role, approximately
40–60% of the total risk (Kendler et al., 2008). At least 396 genes
related to DA were summarized by researchers in 2008 (Li et al.,
2008). Additional genes were found to be associated with DA by
NIDA genetics experts and other individual scientists (Saccone
et al., 2008, 2009). Indeed, studies on DA, CNS diseases, and
relevant research have been steadily proliferating. Concomitantly,
the quantity and quality of molecular therapies for DA and CNS
disorders are advancing, thanks in part to rapid technology devel-
opment in biochemistry, biophysics, and pharmacology, as well as
the breakthrough discoveries of opioid-ligand co-crystallographic
structures (Granier et al., 2012; Manglik et al., 2012; Thompson
et al., 2012; Wu et al., 2012). Unfortunately, the venues or
reports that publicize DA and neuromedicine research are scat-
tered in journals, periodicals, or in databases, such as SciFinder,
PubChem, ChEMBL (Bender, 2010; Gaulton et al., 2012), and
DrugBank (Wishart et al., 2006, 2008; Knox et al., 2011). It is
inconvenient to find, associate and validate reported DA and
neuro-active molecules and reuse the reported results for further
studies. It is thus essential to centralize reported chemogenomics
research data related to DA chemicals and CNS medications in
order to benefit researchers across broad disciplines.
Today, a few medications have been developed and used in the
clinic for DA treatment, and most of them are targeting at GPCRs
www.frontiersin.org February 2014 | Volume 5 | Article 3 | 1
Xie et al. Cloud-computing drug-abuse GPCRs chemogenomics knowledgebase
or transmembrane proteins in brain CNS system. For example,
methadone, buprenorphine, and naltrexone are available for indi-
viduals addicted to opioids, whereas nicotine preparations and
medications (varenicline and bupropion) are available for treat-
ment of tobacco addiction. Some unintended consequences of
these treatments, however, are causes for concern. For exam-
ple, long-term methadone treatment can cause negative changes
in the brain, according to recent studies (Andersen et al., 2012;
Sankararaman et al., 2012). Methadone use accounted for more
than 30 percent of overdose deaths from prescription painkillers
in the US, despite accounting for only 2 percent of pain pre-
scriptions as reported by the Center for Disease Control and
Prevention (CDC, 2014). As such, there remains a great demand
for design and discovery of new medications for the treatment of
DA by targeting at GPCRs.
Another major challenge in the development of CNS drugs
for DA treatment is the polypharmacology associated with
GPCRs and other CNS targetingmolecules. Polypharmacology is
defined as the activity of compounds on multiple targets (Peters,
2012). Methadone, for example, can interact with at least theμ, δ,
and κ opioid receptors, an important rhodopsin or class A GPCR
family. Likewise, a number of medicines that target the CNS dis-
eases can also modulate the DA-related proteins, which can act
in concert with controlled psychoactive substances and increase
side effects. The atypical antipsychotic drug clozapine, for exam-
ple, shows antagonist activity at multiple aminergic GPCR family,
such as the 5HT, dopamine, muscarinic, histamine, and adren-
ergic receptors, some of which are associated with efficacy and
others with side effects (Morphy et al., 2004; Morphy, 2012).
More examples can be found in the current literature (Kroeze
and Roth, 2012). Another important consideration is that DA
and addiction often co-occur with other mental illnesses (Regier
et al., 1990). When an individual experiences addiction to more
than one drug at the same time (so called polydrug addiction),
he/she carries more risk than one addicted to a single drug, due
to an increase in side effects and drug synergy. Data from the
DA Warning Network indicate that the majority of patients with
prescriptions for benzodiazepines or opioids who are admitted
to the emergency room had recently used one or more other
substances, most frequently alcohol (SAMHSA, 2009). The ideal
treatment should therefore break the addiction to each drug. The
design of medicines for DA treatment must address the polyphar-
macology problem through: (i) lessening unwanted off-target
activities that may lead to adverse drug reactions; and (ii) design-
ing polypharmacological drugs with multiple activities across
DA-related target classes, such as GPCRs, ion channels, or kinases
for improved therapies (Peters, 2012). It is advantageous to utilize
a polypharmacological approach in this manner to treat polygenic
diseases, such as DA, in which a network of disease-related targets
are modulated, as opposed to “switching” a single target on or off.
Indeed, we have developed and implemented chemical genomics
as a novel, powerful tool to address polydrug addiction networks
related to these complicated concerns and challenges.
In this manuscript, we reported an integrated platform of
cloud computing and cloud sourcing DA chemogenomics knowl-
edgebase (DA-KB) for CNS system pharmacotherapy and new
medicinal drug discovery (www.CBLigand.org/DAKB, or www.
CBLigand.org/CloudDA). Domain-specific DA-KB database and
polypharmacological target identification methods were con-
structed using our recently published chemogenomics based
TargetHunter program (Wang et al., 2013), and GPU-accelerated
machine learning/cheminformatics/bioinformatics algorithms
and tools (Ma et al., 2011a,b, 2013; Myint et al., 2012). As
reported, chemical genomics (or chemogenomics) is an interdis-
ciplinary research field that utilizes chemicals/drugs and associ-
ated genomics data produced by in vitro and in silico techniques to
systematically identify, analyze and/or predict chemicals-protein
interactions for the purpose of enhancing new medicine design.
Computational chemogenomics draws from the chemoinfor-
matics and bioinformatics disciplines to produce useful infor-
mation systems for researchers in pursuit of chemogenomics
data, predictive modeling, as well as techniques in ligand-
and structure-based drug design (Jacoby, 2011). It transforms
the one-target-one-drug development process to a new multi-
target-multi-drug paradigm; as such it is appropriate for the
study of polydrug polypharmacology networks of DA chemi-
cals and their analogs related to DA-targeted proteins. We have
applied our developed chemogenomics database and machine-
learning algorithms/tools above, and aimed at polypharmacol-
ogy prediction for DA research and treatment through cloud
computing and sourcing services. Herein, we reported our DA
domain-specific chemogenomics knowledgebase (KB) by data-
mining literature and public databases to archive DA chemical
molecules/substances and the protein targets associated DA sig-
naling pathways. Specifically, we analyzed DA related GPCRs and
the poly-pharmacophore effects of their ligands. This information
together with our established computational technologies/tools
can enable us to further analyze the DA in molecular and systems
pharmacology levels, and help us to understand better the DA
mechanism of actions. Ultimately, the constructed computational
chemogenomics knowledgebase databases and developed com-
putational technologies/tools will help bridge the knowledge gap
between chemical structures and their biological activities related
to DA, and assist scientists to conduct polypharmacological tar-
get identification and design better medicines for DA interven-
tion for translational systems pharmacotherapy and personalized
medicine research.
MATERIALS AND METHODS
DRUG ABUSE (DA) DOMAIN-SPECIFIC CHEMOGENOMICS
KNOWLEDGEBASE (DA-KB)
We have data-mined DA related genes, proteins and compounds
as well as associated signaling pathways from literature and public
databases, and then compiled them into the DA-KB database. In
addition, FDA approved CNS drugs also are included in order to
study drug repurposing and the possible side effects or off-target
effects, as many of these therapeutic drugs can also potentially
interact with the DA-related proteins.
The DA-KB contains genes, proteins, chemical compounds,
and bioassays related to DA and neuropharmacology. The current
version of DA-KB consists of the following records:
• DA Genes/Proteins (current: 594 records): the reported genes
related to DA (e.g., GPCRS, transporters, ion channels, and
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kinases) have been data-mined from literature and public
databases, e.g., Knowledgebase for Addiction Related Genes
(KARG, karg.cbi.pku.edu.cn/), and NIDA Center for Genetic
Studies (nidagenetics.org/Results/cand_genes.xls). These genes
were then mapped onto proteins.
• DA Chemicals (current: 0.5 million records): these DA-related
chemicals/substances are the known US controlled Illicit drugs
and/or have been reported biologically to interact with the
proteins above. All of them have been archived from jour-
nal articles, patents and public repositories such as PubChem
and ChEMBL (Bender, 2010; Gaulton et al., 2012), using
our established data-mining protocols and controlled vocabu-
lary/ontology. Among these compounds, 197 of US Illicit drugs
are included. We also incorporate the CNS drugs reported
in the DrugBank database and the PubChem library for later
study of polypharmacology and drug repurposing (Ashburn
and Thor, 2004; Oprea et al., 2011).
• DA Pathways (current: 594 records): The corresponding sig-
naling pathways for DA proteins have been mapped through
public databases, such as KEGG (Kanehisa and Goto, 2000;
Kanehisa et al., 2012) and DrugBank (Wishart et al., 2006,
2008; Knox et al., 2011) using our established data mining
analysis tools.
• DA Bioassays (current: 49,482 records): The bioassays that can
be used to validate the DA target predictions/modeling have
been collected from literature and public resources, such as
ChEMBL and PubChem (Xie, 2010). Such information on
bioassay validation is certain to enhance collaborations among
the broad scientific community.
DA-KB is not a new-born database. Actually it was rooted from
our established web-interfaced cannabinoid molecular informa-
tion database (CBID) repository (www.CBligand.org/cbid) (Yang
et al., 2012), which was constructed using MySQL/PHP and
implemented with our in-house cheminformatics tools/data-
mining algorithms. The current DA-KB platform is disseminated
via cloud sourcing server (www.CBLigand.org/CloudDA). The
current online cheminformatics tools/programs under the GPU-
acceleration computing (Ma et al., 2011a) include Target/Off-
Target Predictors (TargetHunter and HTDocking) (Wang et al.,
2013; HTDocking, 2013) for polydrug addiction/toxicity predic-
tion, artificial neural network (ANN)-QSAR (Myint et al., 2012)
and a blood-brain-barrier (BBB) predictor (Wang and Xie, 2010).
All these have been integrated to meet the needs of the broad DA
research community (Figure 1).
HTDocking FOR DA POLYDRUG ADDICTION ANALYSIS
We have established a high-throughput docking program
(HTDocking, 2013, www.cbligand.org/HTDocking), which is a
web-based computing tool that automates docking procedure
to search for protein targets and explore ligand/protein inter-
actions. In addition, we also published online high-throughput
GPCRs docking program (GPCRDocking, www.CBLigand.org/
GPCRHTDocking) to facilitate DA GPCRs target/off-target map-
ping analysis. In the current version of DA-KB database, 3888
crystal structures of DA-related proteins have been collected from
the Protein Data Bank (PDB) (Berman et al., 2000) to build a DA
domain-specific subset by searching with sequences from our DA-
KB. Water molecules and ligands were removed, and the active
site(s) of each protein were defined by the residues around the
co-crystalized ligands or manually generated using our published
method (Chen et al., 2007). Docking scores are used to assess and
rank the potential protein partners of a queried compound. In
this study, HTDocking and GPCRDocking programs were used to
perform polypharmacology/polydrug addiction analysis for DA
related GPCRs, other proteins and their ligands.
TargetHunter FOR DA FOR POLYPHARMACOLOGY
TargetHunter web server has been developed and used in collab-
oration with the NIGMS-funded UPCMLD center (Brummond
et al., 2012). It has also been employed to predict the off-targets of
a class of novel PKD1 inhibitors, which has been further validated
by experiments (Tandon et al., 2012). The detailed description of
the TargetHunter algorithm has been recently published (Wang
et al., 2013). The underlying principle of the TargetHunter pro-
gram is based on a known medicinal chemistry concept: struc-
turally similar compounds have similar physical properties that
may result in similar biological profiles (Martin et al., 2002;
Pozzan, 2006; Xie and Chen, 2008). In our reported studies using
the public source databases, e.g., ChEMBL and PubChem, the
prediction accuracy was 91.1% in a subset of ChEMBL (Wang
et al., 2013). TargetHunter is a powerful cloud computing tool
with attractive features: (i) ease of use; (ii) query data retrieval
function; (iii) user choices of desired fingerprints and databases;
and (iv) high accuracy. Importantly, we have innovatively imple-
mented a BioassayGeoMap program to facilitate users, simply via
a click “Bioassay Finder,” to easily find the laboratories who have
published bioassay(s) for biological validation. Such an integrated
tool will assist researchers to conduct target/off-target identifi-
cation and develop bioactive compounds for DA treatment as
illustrated below.
RESULTS AND DISCUSSION
GPCRs AND DRUG ABUSE
The DA-KB database provides chemogenomics data informa-
tion and integrated cheminformatics tools/programs to allows
us transform data to knowledge by analyzing the DA in both
molecular and system pharmacology levels. For example, it is
reported that the nucleus accumbens (NAc) and the ventral
tegmental area (VTA) are the primary sites where drugs of abuse
act (Nestler, 2001). Commonly abused drugs interact with recep-
tors such as GPCRs (Table 1) on the cell surface and alter the
dopamine system by prolonging the action of dopamine in the
NAc or by potentiating the activation of neurons in the VTA
and NAc. As such, we first analyzed the GPCRs and DA based
on the established DA-KB. Table 1 lists the 85 GPCRs that are
reported to be closely related to DA and CNS system, includ-
ing well-known cannabinoid receptors (CB1 and CB2), dopamine
receptors (D1−5), histamine receptors (H1−4), opioid receptors
(Mu, Delta and Kappa), and glutamate receptors (Metabotropic
glutamate receptor 1−8). Either the proteins can directly interact
with abused drugs or their mutations in the genes are reported
to associate with DA disorders. For example, the morphine acti-
vates opioid receptors in the VTA, NAc, and cerebral cortex,
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FIGURE 1 | The overview of our integrated DA domain-specific cloud
computing and sourcing platform (CloudDA) with illustration of a
friendly user-interfaced query (A) and output (B) and server backend
(C) of the constructed computational chemogenomics database as
well as the implemented computing tools/programs (D) for DA
research. CloudDA provides the DA chemogenomics knowledgebase,
polydrug addiction/polypharmacology prediction tools, and additional online
services.
results in feelings of reward and activates the pleasure circuit by
causing greater amounts of dopamine to be released within the
nucleus accumbens (Nestler and Malenka, 2004). Cannabinoids
stimulate CB1 receptor (which, like D2 and opioid receptors, are
Gi linked) on glutamatergic and GABAergic nerve terminals in
the NAc, and on NAc neurons themselves (Nestler and Malenka,
2004). In addition, the endocannabinoid contents can be altered
by chronic exposure to nicotine, ethanol or cocaine (González
et al., 2002).
The over-the-counter anti-emetic diphenhydramine (DPH)
has been reported to be abused for non-medicinal purposes. DPH
is an H1 histamine receptor antagonist, and its abuse liability
was confirmed as it interacts either directly or indirectly with
neurotransmitter systems, including those using acetylcholine,
serotonin, norepinephrine, dopamine, opioids or adenosine
(Halpert et al., 2002). These drugs will eventually activate
CREB and FosB in the NAc, and will cause the cellular
adaptations. On the other hand, antagonism of metabotropic
glutamate 1 receptors attenuates behavioral effects of cocaine
and methamphetamine in squirrel monkeys (Achat-Mendes
et al., 2012) and activation of CB2 receptors by CB2 ago-
nists within dopamine terminals can inhibit dopamine release
(Xi et al., 2011; Morales and Bonci, 2012), which implies
the potential of designing molecules targeting these GPCRs
for DA treatment (Achat-Mendes et al., 2012; Yang et al.,
2012).
The distribution information of 85 drug-abuse related GPCRs
in the human body were also collected from the MetaCore
database. Figure 2 shows the statistical abundance of tissue
distribution of these receptors. Most of these receptors are
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Table 1 | List of drug-abuse related GPCRs in the DA-KB database.
GPCR name aUniProt bReported cReported dCited eAbused
accession compounds bioactivities references drug/medication
Adenosine A2a receptor P29274 9253 311 6466 Adenosine
Adenosine A2b receptor P29275 4214 151 3003
Adenosine A3 receptor P33765 9104 298 5550
Alpha-1d adrenergic receptor P25100 3365 113 2072 Lisdexamfetamine*
Alpha-2a adrenergic receptor P08913 3259 174 1831 Benzphetamine*
Alpha-2b adrenergic receptor P18089 2622 86 1375 Methamphetamine*
Alpha-2c adrenergic receptor P18825 2912 102 1503 Methamphetamine*
Angiotensin II type 2 (AT-2) receptor P50052 2255 54 1323
Beta-1 adrenergic receptor P08588 4909 234 3025
Beta-2 adrenergic receptor P07550 6515 208 4320
Beta-3 adrenergic receptor P13945 4925 106 2454
Bradykinin B2 receptor P30411 3114 78 1655
Cannabinoid CB1 receptor P21554 9380 272 5553 Nabilone*
Cannabinoid CB2 receptor P34972 7760 256 4587 Nabilone*
C-C chemokine receptor type 1 P32246 1085 78 727
C-C chemokine receptor type 2 P41597 4594 100 2500
C-C chemokine receptor type 4 P51679 2386 46 1300
C-C chemokine receptor type 5 P51681 4731 133 2931
Cholecystokinin A receptor P32238 3612 105 2081
Cholecystokinin B receptor P32239 2375 125 1743
C-X-C chemokine receptor type 3 P49682 1318 34 864
C-X-C chemokine receptor type 4 P61073 934 58 540
Cysteinyl leukotriene receptor 1 Q9Y271 2631 65 1505
Delta opioid receptor P41143 9268 442 5527 Heroin*
Dopamine D1 receptor P21728 4187 211 2365 (R)-Apomorphine*
Dopamine D2 receptor P14416 10996 590 6945 Ketamine*
Dopamine D3 receptor P35462 6497 356 4289 (R)-Apomorphine*
Dopamine D4 receptor P21917 5207 240 3261 (R)-Apomorphine*
Dopamine D5 receptor P21918 513 77 378
Endothelin receptor ET-A P25101 3839 110 2602
Histamine H1 receptor P35367 4037 267 2717 Diphenhydramine
Histamine H2 receptor P25021 2596 154 1585
Histamine H3 receptor Q9Y5N1 5265 214 3359
Histamine H4 receptor Q9H3N8 2278 118 1357
Interleukin-8 receptor A P25024 2036 33 1142
Interleukin-8 receptor B P25025 2412 58 1465
Kappa opioid receptor P41145 9142 363 5066
Melanocortin receptor 1 Q01726 1747 82 865
Melanocortin receptor 2 Q01718 4 1 1
Melanocortin receptor 3 P41968 3641 89 1864
Melanocortin receptor 4 P32245 7510 143 3869
Melanocortin receptor 5 P33032 3238 72 1647
Mu opioid receptor P35372 9402 396 5600 Morphine*
Muscarinic acetylcholine receptor 1 P11229 6083 282 3646 Cocaine*
Muscarinic acetylcholine receptor 2 P08172 5083 274 3236 Cocaine*
Muscarinic acetylcholine receptor 3 P20309 5345 250 3410
Muscarinic acetylcholine receptor 4 P08173 3174 149 1879
Muscarinic acetylcholine receptor 5 P08912 2900 114 1736
Neurokinin 1 receptor P25103 5328 227 3484
Neurokinin 2 receptor P21452 3400 131 2162
Neuropeptide FF receptor 1 Q9GZQ6 229 4 94
(Continued)
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Table 1 | Continued
GPCR name aUniProt bReported cReported dCited eAbused
accession compounds bioactivities references drug/medication
Neuropeptide Y receptor type 1 P25929 3187 89 2066
Neuropeptide Y receptor type 2 P49146 2585 63 1598
Neuropeptide Y receptor type 4 P50391 88 23 67
Neuropeptide Y receptor type 5 Q15761 1453 62 1227
Nociceptin receptor P41146 2797 87 1488
Platelet activating factor receptor P25105 3787 64 2380
Serotonin 1a (5-HT1a) receptor P08908 6461 452 3967 PMA*
Serotonin 1b (5-HT1b) receptor P28222 2099 198 1497 Bufotenin*
Serotonin 1d (5-HT1d) receptor P28221 2359 181 1456 DOET*
Serotonin 1e (5-HT1e) receptor P28566 221 65 218
Serotonin 1f (5-HT1f) receptor P30939 199 31 146
Serotonin 2a (5-HT2a) receptor P28223 5884 373 4034 Psilocin*
Serotonin 2b (5-HT2b) receptor P41595 3775 196 2227 Mescaline*
Serotonin 2c (5-HT2c) receptor P28335 6102 313 3957 Psilocybin*
Serotonin 4 (5-HT4) receptor Q13639 1192 78 549
Serotonin 5a (5-HT5a) receptor P47898 675 106 639 Lysergide*
Serotonin 6 (5-HT6) receptor P50406 5857 232 3462 Lysergide*
Serotonin 7 (5-HT7) receptor P34969 1899 215 1448
Thyroid stimulating hormone receptor P16473 29856 2 17114
Trace amine-associated receptor 1 Q96RJ0 266 6 148 Amphetamine*
Vasopressin V1a receptor P37288 3037 90 1875
Calcitonin receptor P30988 1803 6 890
Glucagon-like peptide 1 receptor P43220 107911 24 105298
Vasoactive intestinal polypeptide receptor 1 P32241 1768 14 893
GABA-B receptor Q9UBS5 143 7 77 Amobarbital*
Metabotropic glutamate receptor 1 Q13255 961 90 754 JNJ16259685
Metabotropic glutamate receptor 2 Q14416 1201 86 747 LY341495
Metabotropic glutamate receptor 3 Q14832 241 37 149 LY341495
Metabotropic glutamate receptor 4 Q14833 1063 60 572 LY341496
Metabotropic glutamate receptor 5 P41594 2637 103 1742 MPEP
Metabotropic glutamate receptor 6 O15303 218 26 181
Metabotropic glutamate receptor 7 Q14831 125 30 83
Metabotropic glutamate receptor 8 O00222 142 29 114
*US Schedule controlled substances.
aUniProt Accession is from UniProt database(http://www.uniprot.org/)
bNumber of Reported Compounds.
cNumber of Reported Bioactivities.
dNumber of Cited References.
eRepresented Abused Drug/Medication.
PMA, 4-methoxyamphetamine or para-Methoxyamphetamine; DOET, 2,5-Dimethoxy-4-ethylamphetamine; MPEP, 2-Methyl-6-(phenylethynyl)pyridine.
expressed in the primary sites where drugs of abuse act, such as
nucleus accumbens (84), core/shell of nucleus accumbens (78),
and ventral tegmental area (74). Very interestingly, these recep-
tors are also expressed in vision system, such as retina (84),
lacrimal apparatus(82), retinal pigment epithelium (84) and iris
(82), which may help to explain the fact that drug abusers usu-
ally have the signs of unsteady gait bloodshot or watery eyes,
dilated or constricted pupils (Silfies and DeMicco, 2013). It is
well known that some drugs are illegally used for weight loss.
For example, Clenbuterol, a β2 agonist, has been off-label used
as a weight-loss drug (Spiller et al., 2013). Actually, 83 of these
85 GPCR proteins, including β2 adrenergic receptor, can be
found in brown and white adipose tissues. Illegal drugs can affect
fetus or infant (Prenatal Exposure to Drugs of Abuse, 2011), as
these receptors are expressed in umbilical cord (83) and lactat-
ing mammary gland (79). Moreover, these receptors can also
be found in islets of langerhans (81) and pancreas (78), evi-
dence that abused drugs can disturb the functions of pancreas.
This is consistent with the fact that drug use is associated with
worse glycaemic control and higher risk of diabetic ketoaci-
dosis (Lee et al., 2005, 2008, 2009, 2012; Lee and Campbell,
2008).
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FIGURE 2 | Tissue distribution of 85 drug-abuse related GPCRs. Red lines indicate that these tissues are located in the central nervous system (CNS). For
example, 84 of these 85 GPCRs are expressed in the nucleus accumbens, where most drugs of abuse act.
POLYPHARMACOLOGY/POLYDRUG ADDICTION ANALYSIS FOR DA
RELATED GPCRs AND THEIR LIGANDS
To explore the potential interactions between DA/CNS-related
drugs and proteins, we have applied our established HTDocking
program for polypharmacology and polydrug addiction analysis
in order to facilitate research of substance use disorders (SUDs),
psychiatric or co-occurring disorders (CODs) through in sil-
ico molecular mechanism study. High prevalence of SUDs exists
among those who have other mental illnesses and are vulnerable
groups of polydrug or multiple DA use. Polydrug use often car-
ries more risk than the use of a single drug, due to an increase in
side effects and drug synergy. By exploring the molecular partners
(or target proteins) of abused drugs, and further investigating
the associated signaling pathways, we can elucidate the possible
mechanisms of drug synergy, thereby contributing to the rational
design of system pharmacotherapy and personalized medicines.
As illustrated in Figure 3A, multiple targets (small colored nodes)
of six abused drugs were predicted by our HTDocking program.
These predicted top candidate targets (docking score >6.0) as
well as the annotated known targets from DrugBank were com-
piled to build an interacting network or polypharmacology map.
It is not a surprise that our plot shows both benzodiazepines
and barbiturates can bind to GABA-A receptors (green nodes
in Figure 3A), which may explain the synergized CNS depres-
sants effects reported (Li and Xu, 2008). In fact, benzodiazepines
are notorious for causing death when mixed with other CNS
depressants such as opioids, alcohol, or barbiturates.
Among the predicted protein targets, our data show that
PDE5A (yellow node, Figure 3A) is a target shared by codeine and
bromazepam. It is well known that sildenafil (or Viagra), a famous
PDE5A inhibitor, is used for sexual enhancement and can cause
myocardial infarction (Cakmak et al., 2012). To our knowledge so
far, there is no report about direct interactions between codeine
and PDE5A except that some indirect evidence showed that
codeine can induce sexual dysfunction (Ricardo Buenaventura
et al., 2008). In addition, PPARγ (green node, Figure 3A) is the
common target of three compounds: cocaine, bromazepam, and
alprazolam. A drug targeting PPARγ for treatment of diabetes,
e.g., rosiglitazone, is reported to have the side effect of myocar-
dial infarction (Nissen and Wolski, 2007). Such information on
polypharmacological effects will help us better evaluate the risk
of polydrug use and of associated side effects, and could lead the
way to discovery of new neurotherapy.
Another interesting in silico finding is the cross-target effects
of three drugs (methadone, naltrexone, and buprenorphine). Our
HTDocking study shows that besides binding to opioid receptors
(OPRD and OPRM, green nodes), these three drugs are pre-
dicted to interact with carbonic anhydrase 2 (CA2, green node,
Figure 3B). The finding is consistent with literature reports that
drugs targeting CA2 can cause difficulty urinating (Roth et al.,
1992), while difficulty urinating is one of the known adverse
effects of methadone administration. As shown in Figure 3B,
MOA-B (yellow node) is predicted as one of the common tar-
gets of methadone and naltrexone, while A4 (amyloid beta pro-
tein, blue node) is shared by naltrexone and buprenorphine.
Considering that MOAB and A4 are also targets for manage-
ment of Alzheimer’s disease (AD), these predictions could lead to
repurposing these drugs for AD treatment. The experimental val-
idation of the computations-based predictions will be performed
by our collaborators.
DESIGNING POLYPHARMACOLOGY MOLECULES TARGETING GPCRs
FOR DRUG ABUSE TREATMENT
In our DA-KB, we have collected data information on drugs
and therapeutic agents for treatment of substance abuse disor-
ders, as well as drugs for treatment of alcohol and tobacco use
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FIGURE 3 | Illustration of our cloud-based HTDocking server to
predict potential targets (pink nodes) and cross-targets (yellow,
green and blue nodes) of compounds and to explore possible
mechanisms. (A) The predicted targets of six known abused/approved
drugs (opioids: codeine and DB01532; benzodiazepines: bromazepam
and alprazolam; barbiturates: secobarbital and pentobarbital). (B) The
predicted targets of 3 approved drugs for DA treatments (methadone,
naltrexone, and buprenorphine). MAPK10, Mitogen-Activated Protein
Kinase 10; CYP2A6, cytochrome P450, family 2, subfamily A,
polypeptide 6; RAB6A, RAB6A, member RAS oncogene family;
PBRM1, polybromo 1; PDE5A, phosphodiesterase 5A, cGMP-specific;
A4, amyloid beta protein; RB1, retinoblastoma 1; MAPK14,
mitogen-activated protein kinase 14; ALDR, Aldose reductase; PPARg,
Peroxisome proliferator-activated receptor gamma;
GABRA(1-6):Gamma-aminobutyric acid receptor subunit alpha-(1-6);
MAOB, Monoamine Oxidase B; MAP2K1(5), Mitogen-Activated Protein
Kinase 1(5); LCK, Tyrosine-protein kinase Lck; ESR1, Estrogen receptor;
CTDS2, Carboxy-terminal domain RNA polymerase II polypeptide A
small phosphatase 2; GRB14, Growth factor receptor-bound protein 14;
GLR2, AMPA-selective glutamate receptor 2; ALDOA,
Fructose-bisphosphate aldolase A; CA2, Carbonic anhydrase II; OPRD
(OPRM,OPRK), Delta (Mu, Kappa)-type opioid receptor; AA2AR,
Adenosine receptor A2a; MDR1, Multidrug resistance protein 1; GARS,
Glycine-tRNA ligase.
disorders, and their corresponding targets from data-mining lit-
erature reports and public/commercial databases. The current
records consist of 163 drugs/therapeutic agents and 20 associated
proteins. The computing polypharmacology network analyses of
clinical trials or approved therapeutic medicines for DA treat-
ment are illustrated in Figure 4A. The results show four out of
the seven medicines, indicated by small medicine bottles target
the mu-opioid receptor (OPRM, yellow), while two drugs inter-
acting with the cannabinoid receptor 1 (CNR1, green), Nabilone
and Cannabidiol, are in clinical trial for marijuana abuse (Phase
II/III, NCT01347762) and opioid-related disorders (Phase II,
NCT01605539), respectively. These are member of rhodopsin
family GPCRs (Table 1).
We further applied our computational tools to explore the
possibility of designing polypharmacological drug molecules tar-
geting cannabinoid 1, mu-opioid and dopamine D1 for potential
treatment of cocaine craving. As shown in Figure 4, our pilot
study provides an interesting illustration for rational design of
such polypharmacological ligands. By applying our TargetHunter
program, we revealed that some cannabinoid ligands can interact
with opioid receptors and dopamine receptors, which implied the
possibility to design small molecules targeting cannabinoid recep-
tor 1, dopamine receptors and mu-opioid receptor (Figure 4B).
In addition, our established pharmacophore modeling (Chen
et al., 2007) analysis showed that these small molecules shared
common pharmacophoric features among these three receptors
(Figures 4C,D). Such putative pharmacophore information will
be highly useful for medicinal chemists to design and synthesize
multiple-target ligands with synergetic potential for DA treat-
ment. In addition, literature reported that dopamine ligands
prevent the increases in ERK phosphorylation, which result from
cocaine, amphetamine, methamphetamine, and THC adminis-
tration. Thus, dopamine receptor could be a potential target for
DA treatment (Lee and Messing, 2008). Moreover, our in sil-
ico prediction is also congruent with the report by Dong et al
that the CB1-expressing neurons in the NAc are critical for emo-
tional and motivational responses, and the membrane excitabil-
ity of CB1-expressing fast-spiking interneurons within the NAc
shell is increased after withdrawal from cocaine exposure, which
may lead to increased release of GABA (Winters et al., 2012).
Currently, we are carrying out medicinal chemistry synthesis to
design/synthesis and biological test such multi-functional ligands
with the functional pharmacophore groups that can simultane-
ously interact with the three GPCRs for DA treatment. The results
will be reported in a separated journal.
CONCLUSION
Taking together, we reported here a DA domain-specific
chemogenomics knowledgebase repository system (DA-KB or
CloudDA), including the database structure and data records
as well as the implemented chemoinformatics tools/programs.
With the illustrated DA polypharmacology networking analysis
of GPCRs and drugs/therapeutic agents, we have demonstrated
that DA-KB database can provide a powerful tool to transform
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FIGURE 4 | Illustration of TargetHunter webserver (www.cbligand.org/
TargetHunter) for polypharmacology DA research. (A) TargetHunter
mapping literature reported (abused) drugs-targets interactions. The large
(yellow, green, and red) nodes represent targets. The small nodes (pink
and blue) represent drugs, among which, seven, designated by
medicine bottles (blue nodes), are approved/clinical trial medicine for DA
treatments: (i) methadone, naltrexone, oxycodone, and buprenorphine
targeting mu-opiate receptor (OPRM, large yellow nodes); (ii) Nabilone
and Cannabidiol targeting cannabinoid receptor 1(CNR1 or CB1, large
green nodes); and (iii) Adrogolide targeting dopamine receptor 1(DRD1,
red). (B) TargetHunter prediction for possible cross-talk interactions of
cannabinoid (CB) receptors (CNR1 and CNR2; green nodes), opiate
receptors (OPRK, OPRD and OPRM; yellow) and dopamine receptors
(DRD1, DRD2, DRD3, DRD4, and DRD5; red). Small blue and pink
nodes in the center suggest potential cross-talk. (C,D) Pharmacophore
models showing the shared common pharmacophoric features of the
ligands of cannabinoid receptor 1 (CNR1), dopamine receptor D1
(DRD1) and mu-opioid receptor (OPRM).
the data to the knowledge related to DA research. The informa-
tion will help to identify the characteristics and patterns of DA
at the molecular and system pharmacology levels. Exploration of
interactions between chemicals and DA proteins will allow better
understanding of how genes/proteins and small molecules influ-
ence the various risks and protective factors for DA. Considering
the current knowledge of GPCR distribution in the brain, these
data may also help improve and expand our understanding of the
brain circuitry that underlies DA. The impact will be broadened
by our built cloud sourcing and cloud computing web service
that can be accessed worldwide (www.CBLigand.org/CloudDA)
and will certainly boost the data sharing and knowledge exchange
among DA researchers and healthcare providers.
The polypharmacology effects of ligands of DA related GPCRs
are very complex as showed in the preliminary analyses of cross-
targets of opioids, benzodiazepines and barbiturates; target pre-
dictions of the 3 approved DA treatment drugs; and TargetHunter
mapping literature reported (abused) drugs-targets interactions.
The state-of-the-art computational technologies together with
the chemogenomics database enable us to understand the DA in
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systems pharmacology level, for example, predicting the possible
interactions with all the human proteins. Our TargetHunter and
pharmacophoric study further suggested the possibility of finding
and optimizing lead compounds that combine multiple desirable
mechanisms of action on these GPCRs in a single new chemical
entity for DA intervention.
Though our analyses focus on drug-abuse related GPCRs
and their ligands, we believe such studies can be generalized
to other DA related protein target families. As such, the DA-
KB and associated tools will assist biologists to quickly derive
the mechanisms of action for active chemicals used for DA
treatment. They should help quicken target identification by
prioritizing targets or target families according to the strength
of the established associations with structural motifs found in
small-molecule probes. They will also facilitate pharmaceutical
scientists to do research for drug repurposing. Our developed
algorithms and tools can predict new targets of approved drugs,
thus allowing discovery of novel therapies for these drugs (partic-
ularly those that target the CNS) to fulfill unmet clinical needs.
If overlap exists among the DA-related signaling pathways and
those that are modulated by currently approved drugs, it is likely
to repurpose such drugs for DA treatment. Given this insight,
our methods will also address the needs of translational research
that quickly translate basic “data” discoveries into new “knowl-
edge” for clinical pharmacotherapy and personalized medicine
(Collins, 2010).
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